Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Ultra-sensitive Cytokine Assay Services Now Available from PBL

Published: Tuesday, July 16, 2013
Last Updated: Tuesday, July 16, 2013
Bookmark and Share
Assay services for measurement of low abundance biomolecules in human serum or plasma.

PBL InterferonSource has announced the expansion of its assay services portfolio to include 30 different ultra-sensitive biomolecule assays.

Based on an innovative single-molecule counting (SMCI) technology, these services are designed to provide sub-picogram per ml sensitivity for analytes in human serum or plasma.

The background reduction methodology of this detection service extends the linear dynamic range to over 4 logs, allowing high levels of biomarker measurement with minimal dilution in many disease states.

“We are proud to add ultra-sensitive cytokine detection services into our offerings to researchers around the world,” said Dr. Thomas Lavoie, Director of Product Research & Development and Assay Services at PBL.

Dr. Lavoie continued, “The ability to measure basal levels of cytokines and other biomarkers in the femtogram per ml range will enable far deeper analysis of changes in these biomarkers. This enhanced understanding of various diseases and the effects of œtreatments will allow earlier project milestone decisions, saving our clients time, money and concern.”

The addition of ultra-sensitive cytokine detection services signifies PBL’s commitment in providing the best service solutions to meet scientists’ assay needs.

It complements the company’s single-analyte ELISA, cytokine multiplex ELISA, and cell-based activity assay services that are currently offered in their sample testing and screening catalog.

Initial ultra-sensitive assay services by PBL include detection for cytokines such as human IL-17A, IL-17F, IL-17 A/F heterodimer, IL-6, IL-1α, IL-1β, IL-10, IL-15, TNF-α, GLP-1, and biomarkers such as cardiac troponin-I.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
Bacterial Genes Boost Current in Human Cells
Borrowing and tweaking bacterial genes to enhance electrical activity might treat heart, nervous system injury.
Less Frequent Cervical Cancer Screening
HPV-vaccinated women may only need one screening every 5 to 10 years with screening starting later in life.
Cocoa Compound Linked to Some Cardiovascular Biomarker Improvements
The study highlights the urgent need for large, long-term RCTs that improve understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes.
Untangling a Cause of Memory Loss in Neurodegenerative Diseases
The mouse study identifies a possible therapeutic target for a family of disorders.
New Pathway for COPD Biomarker Development
A study from Philip Morris International has highlighted multi-lipid profiling as a potential new pathway for COPD biomarker development.
Stiffening a Blow to Cancer Cells
Researchers develop a way to predict how a tumor tissue's physical properties affect its response to chemotherapy drugs.
Anti-Cancer Drug Uses Tumour mRNA to Identify Responders
Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify patients who will respond to the drug.
New Strategy for Choosing Cancer Drugs
Device can predict tumor responses by measuring cell growth after drug exposure.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos